Li Ke-Zhi, Yin Yi-Xin, Tang Yan-Ping, Long Long, Xie Ming-Zhi, Li Ji-Lin, Ding Ke, Hu Bang-Li
Department of Research, Guangxi Medical University Cancer Hospital, 71 Hedi Road, Nanning, 530021, Guangxi, China.
Department of Radiology, Third Affiliated Hospital of Guangxi Medical University, 13 Dancun Road, Nanning, 530031, Guangxi, China.
Cancer Cell Int. 2021 Apr 15;21(1):211. doi: 10.1186/s12935-021-01901-3.
Cancers located on the right and left sides of the colon have distinct clinical and molecular characteristics. This study aimed to explore the regulatory mechanisms of location-specific long noncoding RNAs (lncRNAs) as competing endogenous RNAs (ceRNAs) in colon cancer and identify potential prognostic biomarkers.
Differentially expressed lncRNAs (DELs), miRNAs (DEMs), and genes (DEGs) between right- and left-side colon cancers were identified by comparing RNA sequencing profiles. Functional enrichment analysis was performed for the DEGs, and a ceRNA network was constructed. Associations between DELs and patient survival were examined, and a DEL-based signature was constructed to examine the prognostic value of these differences. Clinical colon cancer tissues and Gene Expression Omnibus (GEO) datasets were used to validate the results.
We identified 376 DELs, 35 DEMs, and 805 DEGs between right- and left-side colon cancers. The functional enrichment analysis revealed the functions and pathway involvement of DEGs. A ceRNA network was constructed based on 95 DEL-DEM-DEG interactions. Three DELs (LINC01555, AC015712, and FZD10-AS1) were associated with the overall survival of patients with colon cancer, and a prognostic signature was established based on these three DELs. High risk scores for this signature indicated poor survival, suggesting that the signature has prognostic value for colon cancer. Examination of clinical colon cancer tissues and GEO dataset analysis confirmed the results.
The ceRNA regulatory network suggests roles for location-specific lncRNAs in colon cancer and allowed the development of an lncRNA-based prognostic signature, which could be used to assess prognosis and determine treatment strategies in patients with colon cancer.
位于结肠左右两侧的癌症具有不同的临床和分子特征。本研究旨在探讨位置特异性长链非编码RNA（lncRNA）作为竞争性内源性RNA（ceRNA）在结肠癌中的调控机制，并鉴定潜在的预后生物标志物。
通过比较RNA测序图谱，鉴定右侧和左侧结肠癌之间差异表达的lncRNA（DEL）、微小RNA（DEM）和基因（DEG）。对DEG进行功能富集分析，并构建ceRNA网络。检测DEL与患者生存之间的关联，并构建基于DEL的特征以检验这些差异的预后价值。使用临床结肠癌组织和基因表达综合数据库（GEO）数据集验证结果。
我们在右侧和左侧结肠癌之间鉴定出376个DEL、35个DEM和805个DEG。功能富集分析揭示了DEG的功能和参与的通路。基于95个DEL-DEM-DEG相互作用构建了ceRNA网络。三个DEL（LINC01555、AC015712和FZD10-AS1）与结肠癌患者的总生存相关，并基于这三个DEL建立了预后特征。该特征的高风险评分表明生存较差，提示该特征对结肠癌具有预后价值。对临床结肠癌组织的检测和GEO数据集分析证实了结果。
ceRNA调控网络提示位置特异性lncRNA在结肠癌中的作用，并促成了基于lncRNA的预后特征的开发，可用于评估结肠癌患者的预后并确定治疗策略。
